Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350238 | 0.86 | CA1 (0.41) | CA1CA2CA9KIF11ALDH1A1 | |
| SCHEMBL12390582 | 0.85 | PDE2A (0.51) | PDE2ACA1CA2CA9KIF11 | |
| SCHEMBL25530871 | 0.81 | CA1 (0.40) | PDE2ACA1CA2CA9KIF11 | |
| SCHEMBL15803005 | 0.81 | KDM4E (0.40) | PDE2ACA1CA2CA9KIF11 | |
| SCHEMBL7834941 | 0.80 | CA1 (0.42) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL10064802 | 0.79 | NOTUM (0.41) | CA1CA2CA9KIF11TRPV1 | |
| SCHEMBL12828080 | 0.79 | CA1 (0.42) | CA1CA2CA9TRPV1ALDH1A1 | |
| SCHEMBL13698781 | 0.79 | CA1 (0.42) | CA1CA2CA9TRPV1ALDH1A1 | |
| SCHEMBL5175739 | 0.79 | SCN9A (0.46) | KCNN4ALDH1A1ALOX5AP | |
| SCHEMBL13918953 | 0.78 | KDM4E (0.49) | PDE2ACA1CA2CA9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| US-9321760-B2 | Aminopyrimidine derivatives for use as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20150225409-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ABBVIE INC. | 2015-08-13 | — | — | US | disclosed |
| US-9029361-B2 | Agents for treating pain and uses thereof | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140235593-A1 | SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140171423-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235593-A1 | SUBSTITUTED 2-ALKYL-1-OXO-N-PHENYL-3-HETEROARYL-1,2,3,4-TETRAHYDROISOQUINOLINE-4-CARBOXAMIDES FOR ANTIMALARIAL THERAPIES | QTRT1, GLS2, QTRT2 | PDE2A 1028/4885CA1 4384/4885CA2 1465/4885 |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | PDE2A 2463/4885CA1 2055/4885CA2 2902/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | PDE2A 2921/4885CA1 3556/4885CA2 4284/4885 |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | PDE2A 2463/4885CA1 2055/4885CA2 2902/4885 |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | PDE2A 1362/4885CA1 1956/4885CA2 2112/4885 |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | PDE2A 1638/4885CA1 1259/4885CA2 1853/4885 |
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | PDE2A 4309/4885CA1 2741/4885CA2 2445/4885 |
| US-20140171423-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ACHE, MPO, CALCA | PDE2A 103/4885CA1 85/4885CA2 21/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | PDE2A 2775/4885CA1 2841/4885CA2 3610/4885 |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | DPYD, DUT, TYMP | PDE2A 2442/4885CA1 2509/4885CA2 3590/4885 |
| US-20150225409-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ACHE, MPO, CALCA | PDE2A 103/4885CA1 85/4885CA2 21/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PDE2A 2430/4885CA1 4507/4885CA2 3976/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | PDE2A 2463/4885CA1 2055/4885CA2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.